BAL PHARMA LTD.

Bal Pharma Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct. The window will be shut from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The specific date for the board meeting to approve these results will be communicated separately.

Bal Pharma Ltd clarifies that the filing of a statement of deviation/variation in the utilization of funds is not applicable for the quarter ended March 31, 2026. This is because the company has not raised funds through public issue, rights issue, preferential issue, QIP, etc., and has no outstanding proceeds from earlier issues for utilization during the specified quarter.

Bal Pharma Ltd. announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board recommended a dividend of ₹1.20 per equity share (12%), subject to shareholder approval. They also approved the grant of 5,00,000 stock options to employees and a preferential issue of 10,00,000 warrants to promoters. Additionally, Murugesh & Co was appointed as Internal Auditors and G.N.V & Associates as Cost Auditors for FY 2025-26. Mr. Shreepada ML was appointed as Company Secretary and Compliance Officer.

Bal Pharma Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board recommended a dividend of ₹1.20 per equity share, subject to shareholder approval. They also appointed Murugesh & Co as Internal Auditors and G.N.V & Associates as Cost Auditors for FY26. Additionally, the board approved granting 5,00,000 stock options to employees and a preferential issue of 10,00,000 warrants to promoters. Mr. Shreepada ML was appointed as Company Secretary and Compliance Officer.

Bal Pharma Ltd has announced that in addition to the previously announced agenda items for the board meeting scheduled on May 27, 2026, the board will also consider and approve a proposal for fund raising through a preferential issue of warrants to promoters. This announcement is a continuation of the earlier intimation dated May 18, 2026, regarding the board meeting.

Bal Pharma Ltd has scheduled a Board of Directors meeting on May 27, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a dividend, if any, for the financial year ended March 31, 2026, and appoint Internal Auditors & Cost Auditors for F.Y 2025-26. Additionally, the board will approve the grant of stock options to employees under the “Bal Pharma Ltd — Employee Stock Option Plan -2025”. The trading window for dealing in the company's securities has been closed from April 1, 2026, until the close of business hours on May 29, 2026.

Bal Pharma Ltd has announced the closure of the trading window for dealing with the securities of the company for the quarter and financial year ended 31/03/2026. The closure is in accordance with the company's code of conduct and the amended provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be closed from 18th April 2026 and will remain closed until 48 hours after the declaration of the audited financial results. The date of the board meeting for the declaration of the audited financial results is yet to be intimated to the exchange.

Bal Pharma Ltd. has announced its unaudited standalone financial results for the quarter and nine months ended 31.12.2025. The company's revenue from operations stands at ₹ 8,749.48 Lakhs, with a net profit of ₹ 194.62 Lakhs. The results have been reviewed by the Audit Committee and approved by the Board of Directors. The standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015.

Bal Pharma Ltd has announced its unaudited standalone financial results for the quarter ended 31.12.2025. The total income for the quarter is Rs. 8,783.99 Lakhs, with revenue from operations being the major contributor at Rs. 8,749.48 Lakhs. The total expenses for the quarter stood at Rs. 8,689.37 Lakhs. The company reported a net profit of Rs. 194.62 Lakhs for the quarter. The earnings per share (EPS) for the quarter is Rs. 1.92. The company operates in the pharmaceuticals segment only.

Bal Pharma Ltd has announced the closure of its trading window from 1st January 2026 to 16th February 2026. This closure is for the announcement of unaudited financial results for the quarter ended 31.12.2025. The decision is in accordance with the Code of conduct of the Company and the amended provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing with the securities of the Company will be closed for 'designated persons' and their immediate relatives from 18th January 2026 up to 48 hours after the declaration of the unaudited financial results. The date of the Board meeting for the declaration of the unaudited financial results is yet to be intimated to the exchange.